# US 2016/0354542 A1 · Measurement of Glucose in an Insulin Delivery Catheter by Minimizing the Adverse Effects of Insulin Preservatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354542 A1
- Document ID: US20160354542A1
- Status: Published application
- Kind: A1
- Application number: 15/169,432
- Filed: 2016-05-31
- Published: 2016-12-08
- Earliest claimed: 2015-06-03
- Assignees: Pacific Diabetes Technologies, Inc.
- Inventors: William Kenneth Ward; Robert S. Cargill; Gabriel Heinrich; Sheila Benware; Mark Vreeke; Joseph D. Kowalski; Thomas Seidl
- Web page: https://patentgrep.com/patent/US20160354542A1

## CPC

- A61M 5/1723: {using feedback of body parameters, e.g. blood sugar or pressure}
- A61B 5/14503: {invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors (A61B5/1459, A61B5/1464, A61B5/1473, A61B5/1482, A61B5/14865 take precedence)}
- A61B 5/14532: {for measuring glucose, e.g. by tissue impedance measurement}
- A61B 5/1473: invasive, e.g. introduced into the body by a catheter
- A61M 5/142: Pressure infusion, e.g. using pumps
- A61M 5/158: Needles {for infusions; Accessories therefor, e.g. for inserting infusion needles, or for holding them on the body}
- A61M 5/165: Filtering accessories, e.g. blood filters, filters for infusion liquids (A61M1/34, A61M5/36 take precedence)
- A61M 2005/1587: {suitable for being connected to an infusion line after insertion into a patient}
- A61M 2230/005: Parameter used as control input for the apparatus
- A61M 2230/201: Glucose concentration
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)

## Abstract

This disclosure teaches the concept, and method of creating, a dual use device intended for persons who take insulin. In one embodiment, the novel device is an insulin delivery cannula, the outer wall of which contains electrodes, chemical compounds and electrical interconnects that allow continuous glucose sensing and delivery of data to a remote device. Heretofore, the main problem in attempting to sense glucose at the site of insulin delivery has been the high current resulting from oxidation by the sensor of the preservatives in the insulin formulations. One means of eliminating these interferences is to poise the indicating electrode(s) of the sensor at a bias sufficiently low to avoid the signal from oxidation of the preservatives. One way of obtaining a glucose signal at a low bias is to use an osmium-ligand-polymer complex instead of conventional hydrogen peroxide sensing. Another is to use a size exclusion filter located in line with the insulin delivery tubing in order to remove the smaller phenolic preservative molecules while allowing the larger insulin molecules to pass unimpeded. These filtration concepts can also be more broadly applied, that is, the general concept of removal of unwanted drug formulation excipients from a drug delivery system.

## Claims

### Claim 1

A combined drug delivery cannula and continuous glucose sensor that measures glucose without interference from the drug excipient, said cannula being a hollow tube, the outer wall of which includes:
an electrode layer with at least one indicating electrode, said layer underlying
a redox-catalytic layer that includes an osmium compound bound to
a ligand, and either glucose oxidase or glucose dehydrogenase.

### Claim 2 (depends on 1)

The invention of claim 1 in which the drug is an insulin or insulin analog formulation.

### Claim 3 (depends on 1)

The invention of claim 1 in which the indicating electrode material is gold, carbon, or platinum.

### Claim 4 (depends on 1)

The invention of claim 1 in which the ligand is pyridine- or imidazole-based.

### Claim 5 (depends on 4)

The invention of claim 4 in which the ligand is 4,4′-dimethyl-2,2′-bipyridine.

### Claim 6 (depends on 1)

The invention of claim 1 in which the osmium-ligand complex is bound to either poly (4-vinyl pyridine) or poly (1-vinyl imidazole).

### Claim 7 (depends on 1)

The invention of claim 1 in which the excipient is phenol and/or m-cresol.

### Claim 8 (depends on 1)

The invention of claim 1 in which a reference electrode is also disposed on the outer cannula wall.

### Claim 9

A combined insulin delivery cannula and continuous glucose sensor that measures glucose without interference from insulin preservatives, said cannula being a hollow tube, the outer wall of which contains the following layers:
an insulating layer which underlies and is coupled to
a metal layer, the thickness of which is at least 2 μm, which underlies and is coupled to
an electrode layer that includes at least one indicating electrode film, the thickness of which is less than 500 nm, said electrode layer underlying a redox-catalytic layer that includes an osmium compound, bound to a pyridine- or imidazole-based ligand and to a pyridine- or imidazole-based polymer, and either glucose oxidase or glucose dehydrogenase.

### Claim 10 (depends on 9)

The invention of claim 9 in which the insulin preservatives are phenol and/or m-cresol.

### Claim 11 (depends on 9)

The invention of claim 9 in which the insulating layer is polyimide or liquid crystal polymer.

### Claim 12 (depends on 9)

The invention of claim 9 in which the metal layer is titanium, gold, or platinum.

### Claim 13 (depends on 9)

The invention of claim 9 in which the indicating electrode film material is gold, carbon, or platinum.

### Claim 14 (depends on 9)

The invention of claim 9 in which a reference electrode is also disposed on the cannula wall.

### Claim 15 (depends on 9)

The invention of claim 9 in which the pyridine- or imidazole-based ligand is 4,4′-dimethyl-2,2′-bipyridine.

### Claim 16 (depends on 9)

The invention of claim 9 in which the pyridine- or imidazole-based polymer is poly(1-vinylimidazole) or poly(4-vinylpyridine).

### Claim 17

An infusion line, designed for the delivery of medication, containing a size exclusion filter designed for removal of an excipient in the medication formulation.

### Claim 18 (depends on 17)

The invention of claim 17 in which the medication is an insulin or insulin analog formulation.

### Claim 19 (depends on 17)

The invention of claim 17 in which the excipient is phenol and/or m-cresol.

### Claim 20 (depends on 17)

The invention of claim 17 in which the size exclusion material is crosslinked dextran, carbon, alumina, silicate, combined alumina-silicate, Zeolite, a non-dextran carbohydrate, or a molecular sieve material.

### Claim 21 (depends on 18)

The invention of claim 18 in which at least 90% of the insulin or insulin analog is delivered to the user.

### Claim 22 (depends on 19)

The invention of claim 19 in which at least 60% of the phenol and/or m-cresol is removed.

### Claim 23 (depends on 17)

The invention of claim 17 in which the filtered eluent passes through a subcutaneous or intravenous delivery cannula which delivers said eluent to the body of a mammalian user.

### Claim 24 (depends on 18)

The invention of claim 18 in which the filtered insulin-containing eluent passes through an insulin delivery cannula with glucose sensing capability before being delivered to the body of a mammalian user.

### Claim 25

An insulin infusion line that contains an in-line size exclusion filter designed for removal of preservatives from an insulin formulation, said filter allowing the insulin or insulin analog to pass without removal.

### Claim 26 (depends on 25)

The invention of claim 25 in which the preservative is phenol and/or m-cresol.

### Claim 27 (depends on 25)

The invention of claim 25 in which the size exclusion material is crosslinked dextran, carbon, alumina, silicate, combined alumina-silicate, Zeolite, a non-dextran carbohydrate, or a molecular sieve material.

### Claim 28 (depends on 25)

The invention of claim 25 in which at least 90% of the insulin or insulin analog is delivered to the user.

### Claim 29 (depends on 26)

The invention of claim 26 in which at least 60% of the phenol and/or m-cresol is removed.

### Claim 30 (depends on 25)

The invention of claim 25 in which the filtered insulin-containing fluid passes through an insulin delivery cannula which delivers the filtrate to the body of a mammalian user.

### Claim 31 (depends on 30)

The invention of claim 30 in which said insulin delivery cannula incorporates a glucose sensor disposed on its outer wall.

### Claim 32 (depends on 30)

The invention of claim 30 in which a bias potential is maintained on conductive size exclusion filtration material immersed in conductive fluid so that the filtration efficiency is enhanced by electropolymerization of phenolic preservatives,

### Claim 33 (depends on 32)

The invention of claim 32 in which said filter also containing a reference electrode located within the fluid path.

### Claim 34 (depends on 32)

The invention of claim 32 in which the conductive filter material is carbon.
